354 Stock Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$33.20 |
| 52 Week High | US$38.00 |
| 52 Week Low | US$18.90 |
| Beta | 1.05 |
| 1 Month Change | -7.78% |
| 3 Month Change | 11.41% |
| 1 Year Change | 61.17% |
| 3 Year Change | 73.82% |
| 5 Year Change | 165.30% |
| Change since IPO | 138.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 354 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -3.3% | -1.5% |
| 1Y | 61.2% | -30.8% | 0.9% |
Return vs Industry: 354 exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: 354 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| 354 volatility | |
|---|---|
| 354 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 354 has not had significant price volatility in the past 3 months.
Volatility Over Time: 354's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 197 | Joe Ciaffoni | www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
| 354 fundamental statistics | |
|---|---|
| Market cap | €1.09b |
| Earnings (TTM) | €45.24m |
| Revenue (TTM) | €532.48m |
23.6x
P/E Ratio2.0x
P/S RatioIs 354 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 354 income statement (TTM) | |
|---|---|
| Revenue | US$566.77m |
| Cost of Revenue | US$79.72m |
| Gross Profit | US$487.05m |
| Other Expenses | US$438.89m |
| Earnings | US$48.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.47 |
| Gross Margin | 85.93% |
| Net Profit Margin | 8.50% |
| Debt/Equity Ratio | 341.4% |
How did 354 perform over the long term?
See historical performance and comparison